Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)

导出原文传递

翻译打印收藏纠错

作者： Cui, J.J. ^[1] ; Tran-Dubé, M. ; Shen, H. ; Nambu, M. ; Kung, P.-P. ; Pairish, M. ; Jia, L. ; Meng, J. ; Funk, L. ; Botrous, I. ; McTigue, M. ; Grodsky, N. ; Ryan, K. ; Padrique, E. ; Alton, G. ; Timofeevski, S. ; Yamazaki, S. ; Li, Q. ; Zou, H. ; Christensen, J. ; Mroczkowski, B. ; Bender, S. ; Kania, R.S. ; Edwards, M.P.

作者单位： La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, CA 92121, United States ^[1]

发布时间 2013-11-20

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览4

Journal of Medicinal Chemistry

2011年54卷18期

6342-6363页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)

Journal of Medicinal Chemistry

相似文献

Journal of Medicinal Chemistry

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)

Journal of Medicinal Chemistry

相似文献

Journal of Medicinal Chemistry

相关期刊

检索历史清除